Navigation Links
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Date:5/17/2013

ly beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Contacts:Sanofi Media RelationsSanofi Investor RelationsMarisol PeronSebastien MartelTel: +33 (0) 1 53 77 46 4Tel: +33 (0) 1 53 77 45 45E-mail: mr@sanofi.comE-mail: ir@sanofi.comGlobal Oncology CommunicationsLauren Rose MustoTel: +1 (617) 768-1993Mobile: + 1 (781) 572-1147E-mail: lauren.musto@sanofi.comUS Onc
'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... CHENGDU, China, Oct. 5 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co. Inc. ... of modernized traditional Chinese medicine ("TCM") and generic,pharmaceuticals in ... paid,to its common stock shareholders. The dividend of $0.025 ... 30, 2009, with the actual distribution,occurring on or about ...
... , ROCHESTER, N.Y., Oct. 5 Bausch & Lomb, ... acquired the commercial assets of Tubilux Pharma S.p.A. , ... develops and markets a range of proprietary, over-the-counter, and ... in approximately 30 other countries. , Under the terms ...
Cached Medicine Technology:Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009 2Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 2
(Date:12/26/2014)... CA (PRWEB) December 26, 2014 ... score of 3.1 out of 5. This score reflects ... low level of product specialization, low switching costs and ... is reduced by the low availability of substitutes for ... world price of steel and aluminum, key inputs in ...
(Date:12/26/2014)... December 26, 2014 Plugin and template developers ... Volume 5 Plugin for Final Cut Pro X. , “TransPack ... light tool to pull off an industry professional look” Said ... their hands on TransPack Volume 5, a new level of ... a set of over 50 Final Cut Pro X transitions ...
(Date:12/26/2014)... Philadelphia, PA (PRWEB) December 26, 2014 ... to Work in the state of Pennsylvania for 2014. ... the first statewide programs of its kind in the ... Pennsylvania Foundation, the Pennsylvania Department of Community and Economic ... Human Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... Sept. 11 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that it will web cast the,presentation by Harvey ... CL King Best Ideas Conference in New York on ... be web cast live on NBTY,s web site, (http://www.nbty.com ...
... 11 If you,ve purchased prescription,drugs sometime ... receive some money as,part of a multi-million ... from the AWP Track 2 Settlement Administrator ... access video, audio, text, graphics and,photos for ...
... Black lung disease is not a problem of the ... die from it and associated ailments. , In response, ... R. Saylor, associate professor of mechanical engineering at Clemson ... reducing harmful particulate levels in coal mines. Saylor,s research ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Sept. 11 Wolters Kluwer Health, a,division ... information and business,intelligence for students, professionals, and ... the pharmaceutical industry, announced,today the appointment of ... & Education Unit., Lubeck comes to ...
... docs, says researcher , , THURSDAY, Sept. 11 (HealthDay News) -- ... be the last place you would have a discussion about ... a conversation. , Almost half of those included in ... that prayer was very important to their sense of well-being, ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:CDC awards Clemson researcher $700,000 to study black lung prevention 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Spiritual Beliefs Part of Health Care for Some 2Health News:Spiritual Beliefs Part of Health Care for Some 3
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
...
... Renewal 3 cardiac resynchronization therapy ... and cardiac resynchronization therapy. Features: ... and left ventricular (LV) pacing ... irregular ventricular intervals during conducted ...
... housing. MRI-compatible. Requires a guide sphere ... a standard 1.0 - 1.5 cm burr ... assembly with a white collar. MRI-compatible. ... Sterile; single-use only Guide sphere assembly with ...
Medicine Products: